| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate |
2006-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26c8d93e6ead3f265c9f06100d719150
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fad634257b6946db361ab66645e9c8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6eebdcc1178fa57bdd27bc7cb866506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62eb8d9c591fdba8848dea4724b88a6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_154fd7ec8677827752d73449790686a5 |
| publicationDate |
2006-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006178307-A1 |
| titleOfInvention |
Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor |
| abstract |
This invention pertains to the discoveries that orexin and/or CRF increase NMDAR (N-methyl-D-aspartate receptor)-mediated currents at excitatory synapses onto a subset of dopamine cells in the ventral tegmental area (VTA) in the mammalian brain. The orexin effect can be blocked by an orexin receptor type 1 (OXR1). The CRF effect can be blocked by a CRF receptor 2 (CRF-R2) antagonist or by an inhibitor of the CRF-binding protein (CRF-BP). Methods are provided that exploit these discoveries to modulate NMDAR-mediated currents in vivo and in vitro and to screen for modulators (upregulators or downregulators) of NMDA-mediated currents. In vivo methods include the use of modulators of the orexin and CRF pathways to of mitigate a symptom of substance abuse. The invention also provides methods and compositions for co-administration of modulators that act via the orexin and CRF pathways. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011046064-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009034133-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8691768-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012135465-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009058261-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010249164-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010036401-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015048091-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019382462-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010286201-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019200061-A1 |
| priorityDate |
2005-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |